The company is currently developing a range of drug projects that are mostly based on its Multi Matrix MMX® technology. This technology allows the delivery of active pharmaceutical ingredients mainly into the lumen of the colon through tablet erosion in a delayed and controlled manner. This has the effect that the active pharmaceutical ingredients can be applied to the full length of the colon.

The company’s proprietary clinical development pipeline specifically addresses innovative treatments for Inflammatory Bowel Diseases, with the group's lead product Lialda™ launched in the US market and Zacol NMX® launched for the local market in Italy. In addition, two products are in Phase III, two products in Phase II and another completed Phase I. The group has also five products in preclinical phase.

Leveraging on its MMX® technology Cosmo has developed the following compound drugs against Inflammatory Bowel Disease as well as nutraceuticals:


Graph displaying compound drugs against Inflammatory Bowel Disease as well as nutraceuticals developed by Cosmo
Link to Rifamycin page Link to CB 03-01 page Link to Zacol page Link to Heparin page Link to Rifamycin page Link to Budesonide page Link to Lialda and Mesavant page

Back to top